Efficacy and Safety of 1,064 nm Q-switched Nd:YAG Laser Treatment for Removing Melanocytic Nevi
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yoon Jee | - |
dc.contributor.author | Whang, Kyu Uang | - |
dc.contributor.author | Choi, Won Bok | - |
dc.contributor.author | Kim, Hyun Jo | - |
dc.contributor.author | Hwang, Jae Young | - |
dc.contributor.author | Lee, Jung Hoon | - |
dc.contributor.author | Kim, Sung Wook | - |
dc.date.accessioned | 2021-08-12T03:26:29Z | - |
dc.date.available | 2021-08-12T03:26:29Z | - |
dc.date.issued | 2012-05 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.issn | 2005-3894 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15219 | - |
dc.description.abstract | Background: Until recently, the removal of melanocytic nevi has been performed with a CO2 laser or Er:YAG laser. These lasers have been useful for removing affected spots. However, enlargement of spots or some sequelae, including depressed or hypertrophic scars, could develop as unwanted results. The Q-switched Nd:YAG laser has been used to remove deep-seated melanocytes, such as Ota nevus or tattoos. However, there have been no previous experiments performed to test the efficacy and safety of this laser treatment for melanocytic nevi. Objective: The objective of this study was to investigate the efficacy and safety of the 1,064 nm Q-switched Nd:YAG laser for removing melanocytic nevi, including congenital nevomelanocytic and acquired nevomelanocytic nevi. Methods: Two thousand and sixty four Korean patients with small melanocytic nevi were treated with a Q-switched Nd:YAG laser from 2005 to 2009. High-resolution photographs were taken in identical lighting and positions before and after the six weeks of treatment to observe the procedural efficacy. Results: About 70% of the nevi treated using a 1,064 nm Q-switched Nd:YAG laser were completely removed after one session. The other 30% were completely treated within three sessions. The appearance of sequelae such as hollow scars noticeably decreased compared to the results seen in CO2 or Er:YAG laser treatments. Conclusion: Use of the 1,064 nm Q-switched Nd:YAG laser is a safe and effective treatment modality for melanocytic nevi. (Ann Dermatol 24(2) 162 similar to 167, 2012) | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한피부과학회 | - |
dc.title | Efficacy and Safety of 1,064 nm Q-switched Nd:YAG Laser Treatment for Removing Melanocytic Nevi | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5021/ad.2012.24.2.162 | - |
dc.identifier.scopusid | 2-s2.0-84860632767 | - |
dc.identifier.wosid | 000304076700007 | - |
dc.identifier.bibliographicCitation | Annals of Dermatology, v.24, no.2, pp 162 - 167 | - |
dc.citation.title | Annals of Dermatology | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 162 | - |
dc.citation.endPage | 167 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001661786 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | ND-YAG LASER | - |
dc.subject.keywordPlus | SELECTIVE PHOTOTHERMOLYSIS | - |
dc.subject.keywordPlus | ALEXANDRITE | - |
dc.subject.keywordPlus | OTA | - |
dc.subject.keywordAuthor | Melanocytic nevi | - |
dc.subject.keywordAuthor | Nevi | - |
dc.subject.keywordAuthor | Q-switched Nd:YAG | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.